Global Sepsis Diagnostic Market Research, 2030
The global global sepsis diagnostic market was valued at $569.49 million in 2020, and is projected to reach $1.2 billion by 2030, growing at a CAGR of 7.8% from 2021 to 2030.
Sepsis is a potentially fatal illness that arises when the body's immune system attacks its own tissues in reaction to an infection. When the infection-fighting processes turn on the body, they cause organs to function poorly and abnormally. Septic shock can develop from sepsis. This is a sudden reduction in blood pressure that can cause serious organ damage and even death. Treatment with antibiotics and intravenous fluids as soon as possible enhances the chances of survival.
Sepsis diagnostic is expected to exhibit significant market growth during the forecast period, owing to increase in burden of sepsis and rise in global geriatric population. The key factors driving the growth of market are attributed to increase in government funding for sepsis-related research activities and rise in prevalence of infectious disease further drive the market growth. However, high costs automated diagnostics devices restrict the market growth. Conversely, development of rapid diagnosis/point-of-care techniques for early sepsis diagnostics are anticipated to provide lucrative opportunities to the key market players during the forecast period.
The global sepsis diagnostic market is segmented on the basis of type of product, technology, methods, usability, pathogen, and region. According to type of product, the market is divided into blood culture media, instruments, assay kits & reagents, and software. On the basis of technology, the market is segregated into microbiology, molecular diagnostics, immunoassays, and flow cytometry. By method, the market is divided into conventional diagnostics and automated diagnostics. Depending on usability, it is segregated into laboratory testing and point-of-care testing. On the basis of pathogen, market is divided into bacterial sepsis, fungal sepsis, and other pathogen. Regionally, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Coronavirus (COVID-19) was discovered in December 2019 in Hubei province of Wuhan city in China. The disease is caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted among humans.
After its discovery in Wuhan, the disease rapidly spread to other parts of the globe. Moreover, this virus causes various symptoms in patients, which range from common symptoms to serious symptoms. For instance, common symptoms include fever, dry cough, and fatigue. However, serious symptoms include difficulty in breathing or shortness of breath, chest pain or pressure, and loss of speech or movement. Furthermore, the virus has high potential of lethality in geriatric population. On March 11, 2020, the World Health Organization made an assessment that COVID-19 can be characterized as pandemic. In addition, only a few vaccines that received emergency approvals for COVID-19 prevention. Thus, social distancing is observed as the most important measure to stop the spread of this disease. Furthermore, to maintain social distancing, various countries across the world have adopted nationwide lockdowns.
The COVID-19 pandemic had a positive impact on the sales of sepsis diagnostics. The global spread of COVID-19 and the emergence of sepsis cases among COVID-19 patients are projected to boost demand for rapid diagnosis, resulting in a faster adoption of devices, reagents, and test kits for sepsis detection. The current global crisis has brought attention to the dangers that older individuals face, as they are more vulnerable to complications such as acute respiratory distress syndrome (ARDS), which is usually caused by pneumonia and raises the risk of sepsis. As a result, there is a greater requirement for early detection of sepsis in patients with COVID-19 infections.
The global sepsis diagnostic market is segmented into Method, Product, Technology, Usability and Pathogen.
By Product Type Segment Review
By product type, the blood culture media segment was the major revenue contributor in 2020, and is anticipated to continue this trend during the forecast period, owing to increase in number of sepsis cases, rise in geriatric population, high incidence of bloodstream infection, growth in demand for rapid diagnostic techniques, and high prevalence of infection diseases. On the other side, the instruments segment is projected to exhibit fastest growth during the forecast period, owing to increase in number of surgical procedures and rise in awareness among people regarding healthcare.
Technology Segment Review
By technology in sepsis diagnostic market size, the microbiology segment presently dominates the market, and is expected to remain dominant during the sepsis diagnostic market forecast period. This is attributed to the fact that microbiological technology allows accurate detection and identification of microorganisms for sepsis diagnosis through the application of culture media test.
Method Segment Review
By method in sepsis diagnostic market size, the conventional diagnostics segment presently dominates the market, and is expected to remain dominant during the forecast period, owing to higher cost of automated diagnostics devices.
Usability Segment Review
By usability, the laboratory testing segment presently dominates the market, and is expected to remain dominant during the forecast period. This is attributed to the fact that lab testing has greater accuracy in comparison to point-of-care testing while diagnosing sepsis. In addition, increase in reliance of patients and physicians on laboratory testing boosts the sepsis diagnostic market growth.
Pathogen Segment Review
By pathogen, the bacterial sepsis segment presently dominates the sepsis diagnostic market share, and is expected to remain dominant during the forecast period, owing to increase in prevalence of hospital-acquired infections, rise of bacterial sepsis cases, and increase in number of surgical procedures.
Region segment review
By region in sepsis diagnostic industry, North America dominated the market in 2020, accounting for the highest sepsis diagnostic market share, and is anticipated to maintain this trend throughout the forecast period. The presence of highly developed healthcare system, high adoption of innovative sepsis diagnostics technology, and technological advancement in the field of sepsis diagnostics are anticipated to drive the market growth.
This report provides comprehensive competitive analysis and profiles of prominent market players of sepsis diagnostic industry such as key players operating in the BioMerieux, Thermo Fisher Scientific Inc., Abbott Laboratories, Inc., Becton, Dickinson and Company, Bruker Corporation, Beckman Coulter, Inc., T2 Biosystems, Inc., Nanosphere, Inc., Hoffmann-LA Roche Ltd., Danaher Corporation.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global sepsis diagnostic market analysis from 2020 to 2030 to identify the prevailing global sepsis diagnostic market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the global sepsis diagnostic market segmentation assists to determine the prevailing sepsis diagnostic market opportunity.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global global sepsis diagnostic market trends, key players, market segments, application areas, and market growth strategies.
Global Sepsis Diagnostic Market Report Highlights
Market Size By 2030
USD 1.2 billion
CAGR of 7.8%
2020 - 2030
Key Market Players
Danaher Corporation, Thermo Fisher Scientific Inc., Bruker Corporation, Becton, Dickinson and Company, Nanosphere, Inc., F. HOFFMANN-LA ROCHE AG, Abbott Laboratories, Inc., CEPHEID INC., BioMerieux SA, T2 Biosystems, Inc
This section provides various opinions of the top-level CXOs in the sepsis diagnostics market industry. In accordance with several interviews conducted, the utilization of sepsis diagnostics techniques is expected to witness a significant rise with increase in disease diagnosis. The sepsis diagnostics market has piqued the interest of the healthcare industry, owing to its high accuracy and precise techniques
The CXOs further added that there have been remarkable advancements and some major developments in this market, such as devices with more throughput and accurate results. Owing to increase in chronic & infectious diseases, use of automated instruments, and rise in awareness regarding healthcare, North America is expected to emerge as a prominent leader in the global sepsis diagnostics market.
According to the perspectives of CXOs of leading companies in the market, rise in prevalence of infectious diseases, increase in cases of hospital-acquired infections, and technological advancements are some of the major factors that drive the growth of the global sepsis diagnostics market. However, high cost of automated diagnostic devices hampers the market growth.
As stated by CXOs, an increase in the incidence of chronic and infectious diseases boosts the demand for sepsis diagnostics techniques, as they are the simplest technique for diagnosis of diseases. Therefore, use of sepsis diagnostics techniques, such as molecular diagnostics, point-of-care testing, and immunodiagnostics, in standalone laboratories and hospitals is expected to fuel the market growth in the future.
In addition, the employment of sepsis diagnostics techniques is highest in North America, owing to increase in use of automated instruments, followed by Europe and Asia-Pacific. Furthermore, use of minimally invasive techniques is expected to boost the growth of the in vitro diagnostics market in Europe and Asia-Pacific.